Skip to main content

Rheumatoid Arthritis

      In this week's podcast, Drs. Artie Kavanaugh and Jack Cush present highlights from the virtual EULAR2020 meeting held June 3-6, 2020. Featured reports include the SELECT-CHOICE study, the EXCEED trial, Avacopan in AAV, BeST mortality outcomes, BLISS-LN study, biosimilars and tofa in systemic sclerosis.
      These were my top abstracts from Thursday, 4th of June at EULAR 2020:
      These were my top abstracts from Thursday, 4th of June at EULAR 2020:
      Every time a big scientific meeting ends I ask myself a question: how is it going to affect the way I treat my patients? This year the question pertains to management of axial spondyloarthropathies and psoriatic arthritis. Actually, this question has been brewing for several years now, but only now we get more data to form more or less feasible answer. So let’s see what EULAR 2020 has to offer.
      Here is my top-five from day one at EULAR:
      In difficult times, it's reassuring to reflect on the similarities that bring us together. In the case of the EULAR and ACR COVID19 guidelines as discussed at #EULAR2020 by Drs. Mikuls and Landewe, the recommendations from both panels proved to be reassuring with a hint of "we are flying blindly into the unknown."
      This week's Tuesday Nite Rheumatology featured Dr Jonathan Kay (U Mass) who gave an update on Biosimilars and took questions the subject. The program was moderated by Dr. Jack Cush.
      ×